Cadrenal Therapeutics, INC. 8-K Filing
Ticker: CVKD · Form: 8-K · Filed: Dec 16, 2025 · CIK: 1937993
| Field | Detail |
|---|---|
| Company | Cadrenal Therapeutics, INC. (CVKD) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2025 |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $10.85, $2.2 million, $10.60, $10,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Cadrenal Therapeutics, INC. (ticker: CVKD) to the SEC on Dec 16, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar); $10.85 (ing"). The offering price per Share is $10.85. The Shares are being offered pursuant); $2.2 million (eeds from the Offering of approximately $2.2 million. The Offering is expected to close on o); $10.60 (mmon Warrants have an exercise price of $10.60 per share. The shares of Common Stock i); $10,000 (e gross proceeds of the Offering; (iii) $10,000 for non-accountable expenses; and (iv)).
How long is this filing?
Cadrenal Therapeutics, INC.'s 8-K filing is 5 pages with approximately 1,624 words. Estimated reading time is 6 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,624 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2025-12-16 08:24:18
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar
- $10.85 — ing"). The offering price per Share is $10.85. The Shares are being offered pursuant
- $2.2 million — eeds from the Offering of approximately $2.2 million. The Offering is expected to close on o
- $10.60 — mmon Warrants have an exercise price of $10.60 per share. The shares of Common Stock i
- $10,000 — e gross proceeds of the Offering; (iii) $10,000 for non-accountable expenses; and (iv)
- $13.5625 — 25% of the Offering price per share, or $13.5625 per share. The foregoing summaries of
Filing Documents
- ea0269824-8k_cadrenal.htm (8-K) — 37KB
- ea026982401ex4-1_cadrenal.htm (EX-4.1) — 110KB
- ea026982401ex4-2_cadrenal.htm (EX-4.2) — 106KB
- ea026982401ex5-1_cadrenal.htm (EX-5.1) — 9KB
- ea026982401ex10-1_cadrenal.htm (EX-10.1) — 235KB
- ex5-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-25-121932.txt ( ) — 794KB
- cvkd-20251215.xsd (EX-101.SCH) — 3KB
- cvkd-20251215_lab.xml (EX-101.LAB) — 33KB
- cvkd-20251215_pre.xml (EX-101.PRE) — 22KB
- ea0269824-8k_cadrenal_htm.xml (XML) — 4KB
01. Entry into a Material Definitive
Item 1.01. Entry into a Material Definitive Agreement. The Offering On December 15, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a securities purchase agreement (the "Purchase Agreement") with certain investors named on the signature pages thereto. The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of: (i) in a registered direct offering, 207,374 shares (the "Shares") of the Company's common stock, $0.001 par value (the "Common Stock"), and, (ii) in a concurrent private placement, unregistered warrants (the "Common Warrants") to purchase up to 414,748 shares of Common Stock (collectively, the "Offering"). The offering price per Share is $10.85. The Shares are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-277835) (the "Registration Prospectus"), and a prospectus supplement, dated December 15, 2025 (the "Prospectus Supplement"), filed with the Securities and Exchange Commission (the "Commission") on December 16, 2025 pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the "Securities Act"). The Company expects to receive gross proceeds from the Offering of approximately $2.2 million. The Offering is expected to close on or about December 16, 2025, subject to the satisfaction of customary closing conditions (the "Closing Date"). In connection with the Offering, the Company and each of its directors and officers entered into Lock-Up Agreements, pursuant to which the parties agreed to be subject to a lock-up for a period of 10 days following the Closing Date, subject to certain exceptions. In addition, pursuant to the Purchase Agreement and subject to certain exceptions, the Company agreed not to, until 10 days from the Closing Date, (i) enter into or effect any issuance of Common Stock or Common
02. Unregistered Sales of Equity Securities
Item 3.02. Unregistered Sales of Equity Securities. The information contained above in Item 1.01 related to the issuance of the Common Warrants, the Placement Agent Warrants, the Common Warrant Shares and the Placement Agent Warrant Shares is hereby incorporated by reference into this Item 3.02. The Common Warrants, the Placement Agent Warrants, the Common Warrant Shares and the Placement Agent Warrant Shares have not been registered under the Securities Act and are instead being offered pursuant to the exemption provided in Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 4.1 Form of Common Stock Purchase Warrant 4.2 Form of Placement Agent Warrant 5.1 Opinion of Blank Rome LLP 10.1 Form of Securities Purchase Agreement, dated as of December 15, 2025, by and among Cadrenal Therapeutics, Inc. and the Purchasers named therein 23.1 Consent of Blank Rome LLP (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 16, 2025 CADRENAL THERAPEUTICS, INC. By: /s/ Quang X. Pham Name: Quang X. Pham Title: Chairman and Chief Executive Officer 3